Combination of Brivanib With 5-Fluorouracil/Leucovorin (5FU/LV) and 5-Fluorouracil/Leucovorin/Irinotecan (FOLFIRI)

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: * Histological/cytological confirmed diagnosis of Gastrointestinal malignancy, except pancreatic cancer * Eligible for 5FU/LV or FOLFIRI chemotherapy * ECOG 0-1 * Able to swallow and tolerate tablets * Life expectancy of 3 months Exclusion Criteria: * Unwilling to use acceptable method to avoid pregnancy of partner/self for the entire study period and up to 4 weeks after last dose * Women who are pregnant or breastfeeding * Pancreatic cancer * Known brain metastasis, evidence of leptomeningeal disease * History of thrombo-embolic disease * Hemorrhage/bleeding events * Uncontrolled or significant cardiovascular disease * Any 3 or more of the following risk factors: arterial thrombosis , smoking, hypercholesterolemia, hypertension, obesity (BMS\>30) and diabetes * Pre-existing thyroid abnormality, not maintained with medication * QTC (Fridericia) \>450 msec on two consecutive ECG's * Subjects with concomitant second malignancies ( except adequately treated non-melanoma skin, in situ carcinoma of bladder, cervix or breast, early prostate cancer) * Any major surgery within 4 weeks of study drug administration * Increased levels of both D-Dimer and Prothrombin fragment 1 +2 * Arm B and C only-positive UGT1A1 genotype of TA7/TA7 * History of allergy of brivanib or drug class * History of severe reactions to fluoropyrimidine therapy or irinotecan * Prior therapy with brivanib